ClinicalTrials.gg
TerminatedNCT01144403Updated Oct 18, 2016Results posted

A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.

A Phase 2 interventional study of Cyclophosphamide and Fludarabine in Diffuse Large B-Cell Lymphoma, sponsored by Hoffmann-La Roche. Terminated at 8 sites in Romania. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-18.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse — 20 open to participants now, 38 under way, 4 of them phase 3. Rituximab · Lymphoma, Large B-Cell, Diffuse.

Enrollment
181st of 211
8 · median 46
Started
2010
with 8 others
Phase 2
119 of 218
12 open now
Registered
106th of 218
by date
Lead sponsor
7 of 218
Hoffmann-La Roche

Among the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse, this one is the 181st largest by enrollment of the 211 interventional ones that give a count, is one of 9 that started in 2010, is one of 119 in phase 2, and was the 106th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

20 of the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse are open now, in 6 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

This multicenter, open-label study will assess the efficacy and safety of MabThera (rituximab) added to standard chemotherapy in participants with untreated Mantle Cell Lymphoma not eligible for autologous stem cell transplantation. Participants will receive MabThera (372 mg/m\^2 intravenously) on Day 1 of each 28-day treatment cycle in addition to standard chemotherapy for 6 cycles. In participants experiencing complete or partial response, MabThera will be continued as consolidation therapy for 2 more cycles.

03

Conditions studied

  • Diffuse Large B-Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult participants, >/=18 years of age
  • untreated Mantle Cell Lymphoma, not eligible for Stem Cell Transplantation
  • known mantle cell lymphoma international prognostic index (MIPI) at diagnosis
  • (ECOG) performance status 0-2
  • adequate hematological, renal and hepatic function

Exclusion criteria

Exclusion Criteria:

  • known to murine proteins or chemotherapy regimen
  • previous therapy
  • history of other within the last 5 years, except for squamous cell carcinoma, basal cell carcinoma of the skin or in situ cervical carcinoma
  • active infection
  • cardiac disease
  • regular treatment in the 4 weeks prior to first dose of study drug
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Rituximab

    Rituximab, 375 milligram per meter square (mg/m\^2) was given intravenously on Day 1 and then every 28 days (+/-7 days) for 6 cycles, followed by 2 consolidated infusions in responders as rituximab induction therapy. Rituximab infusions were administered concomitantly with prescribed chemotherapy i.e., fludarabine, cyclophosphamide and mitoxantrone (maximum 6 cycles).

    Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Mitoxantrone · Drug: Rituximab

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    Overall Response Rate (ORR) was determined by tumor response according to International Workshop Group to Standardize Response Criteria for mantle cell lymphoma (MCL) criteria from confirmed evaluations of both target, radiographically evaluated, and non-target lesions. A responder is defined as a subject experiencing either a complete (CR)/ unconfirmed complete (Cru), or partial response (PR) by these criteria. As per criteria; CR = disappearance of all evidence of disease; CRu = the sum of the product of the diameters (SPD) of multiple nodes decreased by at least 75%; PR = regression of measurable disease and no new sites.

    Time frame: Up to 50 months (approximately)

Secondary outcomes

  1. Overall Survival (OS)

    Overall survival is defined as time from date of enrollment to the date of death, regardless of the cause of death.

    Time frame: From the time of enrollment until death due to any cause (up to 50 months [approximately])

  2. Progression-free Survival (PFS)

    PFS is defined as the interval between the day of enrollment and the first documentation of progressive disease or death. Progression of disease is defined as at least a 20 percent (%) increase in the sum of longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions.

    Time frame: From the time of enrollment until death due to any cause (up to 50 months [approximately])

  3. Number of Participant With Adverse Event (AE)

    An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with study treatment.

    Time frame: Up to 50 months (approximately)

07

Results

Posted Aug 29, 2016
Limitations and caveats
The study was prematurely terminated with 8 participants enrolled, all of them are included into the statistical analyses.

Participant flow

Participant flow — Overall Study
MilestoneRituximab
Started8
Completed3
Not completed5
Withdrew: Lost to follow-up3
Withdrew: Death1
Withdrew: Adverse event1

Outcome measures

PrimaryOverall Response Rate (ORR)

Overall Response Rate (ORR) was determined by tumor response according to International Workshop Group to Standardize Response Criteria for mantle cell lymphoma (MCL) criteria from confirmed evaluations of both target, radiographically evaluated, and non-target lesions. A responder is defined as a subject experiencing either a complete (CR)/ unconfirmed complete (Cru), or partial response (PR) by these criteria. As per criteria; CR = disappearance of all evidence of disease; CRu = the sum of the product of the diameters (SPD) of multiple nodes decreased by at least 75%; PR = regression of measurable disease and no new sites.

Time frame:
Up to 50 months (approximately)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsRituximab
Overall Response Rate (ORR)87.5
SecondaryOverall Survival (OS)

Overall survival is defined as time from date of enrollment to the date of death, regardless of the cause of death.

Time frame:
From the time of enrollment until death due to any cause (up to 50 months [approximately])
Reported as:
Median · days
Overall Survival (OS)
daysRituximab
Overall Survival (OS)927 (0.000 to 2204.066)
SecondaryProgression-free Survival (PFS)

PFS is defined as the interval between the day of enrollment and the first documentation of progressive disease or death. Progression of disease is defined as at least a 20 percent (%) increase in the sum of longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions.

Time frame:
From the time of enrollment until death due to any cause (up to 50 months [approximately])
Reported as:
Median · days
Progression-free Survival (PFS)
daysRituximab
Progression-free Survival (PFS)653 (537.058 to 768.942)
SecondaryNumber of Participant With Adverse Event (AE)

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with study treatment.

Time frame:
Up to 50 months (approximately)
Reported as:
Number · participants
Number of Participant With Adverse Event (AE)
participantsRituximab
Number of Participant With Adverse Event (AE)8

Adverse events

Collected over Up to approximately 50 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab—3/8 (37.5%)8/8 (100%)
Most frequent serious events
Most frequent serious events
EventRituximab
PneumoniaInfections and infestations1/8
NeutropeniaInfections and infestations1/8
ToxicityInjury, poisoning and procedural complications1/8
Most frequent other events
Showing 10 of 19
Most frequent other events
EventRituximab
ThrombocytopeniaBlood and lymphatic system disorders5/8
LeucopeniaBlood and lymphatic system disorders4/8
AnemiaBlood and lymphatic system disorders3/8
Drug EruptionInjury, poisoning and procedural complications2/8
NeutropeniaBlood and lymphatic system disorders2/8
Gastric PainGastrointestinal disorders1/8
Ascending Aorta DilatationVascular disorders1/8
Dermatitis EczematousSkin and subcutaneous tissue disorders1/8
TracheitisRespiratory, thoracic and mediastinal disorders1/8
HyperglycemiaMetabolism and nutrition disorders1/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)Rituximab
Mean60.50 ± 7.964
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab
Female3
Male5
08

Study locations

8 sites
  • Brasov, 500326, Romania
  • Bucharest, 005098, Romania
  • Bucharest, 022328, Romania
  • Bucuresti, 030171, Romania
  • Cluj-Napoca, 400015, Romania
  • Iasi, 700111, Romania
  • Targu-mures, 540136, Romania
  • Timisoara, 300079, Romania
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2010
First posted
Jun 15, 2010
Start
Jun 2010
Primary completionActual
Aug 2014
CompletionActual
Aug 2014
Results first posted
Aug 29, 2016
Last update
Oct 18, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01144403
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 15, 2010
Start date
Jun 2010
Primary completion
Aug 2014
Completion
Aug 2014
Results posted
Aug 29, 2016
Last update
Oct 18, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion